0 Items - $0.00
Categories
A to Z

Alternative structural projections:

Sp-8-pCPT-cGMPS

8- (4- Chlorophenylthio)guanosine- 3', 5'- cyclic monophosphorothioate, Sp- isomer ( Sp-8-pCPT-cGMPS ), sodium salt
Membrane-permeant and PDE-resistant PKG agonist
Cat. No.: C 014
    
CAS No.: [160385-87-5]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: C 014-05
Unit: 5 µmol / ~2.6 mg
$182.00
Specially purified grade, fluorescent impurities removed. For other salt forms please inquire. Activator of protein kinase G type I α and type II. Caution: Protein kinase A type II is activated as well. Excellent cell membrane permeability and phosphodiesterase stability. Detailed technical information and updated reference list available on request. References: Butt et al., Eur. J. Pharmacol., 269, 265 - 268 (1994), Gamm et al., J. Biol. Chem., 270, 27380 - 27388 (1996).
Cat. No. C 014
Patent Information Protected under patents US 5,625,056 and DE 42 17679  issued to BIOLOG LSI
CAS number [160385-87-5]
Purity > 99% HPLC
Salt form Sodium
Storage temperature -20°C / -4°F
Light-sensitive True
Molecular formula C₁₆H₁₄ClN₅O₆PS₂ · Na
Molecular weight [g/mol] 525,9
Modifications 8-cGMP
Target PKG (cGK) Activator
Lipophilicity 2.66
Absorption max [nm] 276
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] 21500
  • 1. Jäger R., Russwurm C., Schwede F., Genieser H.-G., Koesling D.Russwurm M., J. Biol. Chem., 287, 1210 - 1219 (2012), "Activation of PDE10 and PDE11 Phosphodiesterases"
  • 2. Jäger R., Schwede F., Genieser H.-G., Koesling D.Russwurm M., Br. J. Pharmacol., 161, 1645 - 1660 (2010), "Activation of PDE2 and PDE5 cy Specific GAF Ligands: Delayed Activation of PDE5"
  • 3. West G. A., Meno J. R., Nguyen T.-S. K., Ngai A. C., Simard J. M.Winn H. R., J. Cardiovasc. Pharmacol., 41, 444 - 451 (2003), "cGMP-dependent and not cAMP-dependent Kinase is Required for Adenosine-induced Dilation of Intracerebral Arterioles"
  • 4. Spicuzza L., Belvisi M. G., Birrell M. A., Barnes P. J., Hele D. J.Giembycz M. A., Br. J. Pharmacol., 133, 1201 - 1212 (2001), "Evidence that the Anti-Spasmogenic Effect of the Beta-Adrenoceptor Agonist, Isoprenaline, on Guinea-Pig Trachealis is not Mediated by Cyclic AMP-dependent Protein Kinase"
  • 5. Ashur-Fabian O., Perl O., Lilling G., Fridkin M.Gozes I., Peptides, 20, 629 - 633 (1999), "SNV, a Lipophilic Superactive VIP Analog, Acts through cGMP to Promote Neuronal Survival"
  • 6. Wei J.-Y., Cohen E. D., Genieser H.-G.Barnstable C. J., J. Mol. Neurosci., 10, 53 - 64 (1998), "Substituted cGMP Analogs Can Act as Selective Agonists of the Rod Photoreceptor cGMP-Gated Cation Channel"
  • 7. Wang Y.Telfer W. H., Insect Biochem. Molec. Biol., 26, 85 - 94 (1996), "Cyclic Nucleotide-induced Termination of Vitellogenin Uptake by Hyalophora cecropia Follicles"
  • 8. Gamm D. M., Francis S. H., Angelotti T. P., Corbin J. D.Uhler M. D., J. Biol. Chem., 270, 27380 - 27388 (1996), "The Type II Isoform of cGMP-dependent Protein Kinase is Dimeric and Possesses Regulatory and Catalytic Properties Distinct from the Type I Isoforms"
  • 9. Bäumner D.Nawrath H., Eur. J. Pharmacol., 273, 295 - 298 (1995), "Effects of Inhibitors of cGMP-dependent Protein Kinase in Atrial Heart and Aortic Smooth Muscle From Rats"
  • 10. Harris F. M., Wilkins A. C. R., Bayliss M. A., Brenton A. G., Games D. E., Newton R. P., Langridge J. I.Walton T. J., Intl. Symp. Appl. Mass Spec. Health Sci. Spain, 0, 0 - 0 (1995), "Mass Spectrometric Analysis of Novel Effectors of Cyclic Nucleotide-dependent Protein Kinases"
  • 11. Butt E., Eigenthaler M.Genieser H.-G., Eur. J. Pharmacol., 269, 265 - 268 (1994), "(Rp)-8-pCPT-cGMPS, a Novel cGMP-dependent Protein Kinase Inhibitor"